| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 84.08 | 15.0% | 21.2% |
| Total Income | 84.08 | 15.0% | 21.2% |
| Expenditure | 61.72 | 10.7% | 11.2% |
| PBT | -8.21 | 21.2% | 52.0% |
| Net Profit | -8.05 | 24.6% | 53.0% |
| OPM | -5.40% | 3.96pp | 9.31pp |
| NPM | -9.58% | 5.02pp | 15.13pp |
| EPS | -0.12 | 25.0% | 55.6% |
Evolus Reports Strong Second Quarter 2026 Financial Results
06 Aug 2026 · 6 Aug, 1:53 am
Summary
Evolus, Inc. reported strong second quarter 2026 financial results, with global net revenue increasing by 21% year-over-year to $84.1 million. The company achieved its third consecutive quarter of positive Adjusted EBITDA, totaling $4.7 million, a significant improvement from the prior year. Based on this performance, Evolus has raised its full-year 2026 net revenue guidance and increased its adjusted gross profit margin guidance. Management highlighted the increasing momentum of their portfolio focus, significant market share gains, and strategic advancements in their global injectable portfolio.
Key Highlights
- 1
Global net revenue reached $84.1 million for the second quarter of 2026, marking a 21% increase over the prior year.
- 2
The company achieved positive Adjusted EBITDA of $4.7 million for the second quarter of 2026, representing its third consecutive quarter of profitability and a $12.6 million year-over-year improvement.
- 3
Evolus raised its full-year 2026 net revenue guidance to between $330 million and $337 million.
- 4
Adjusted gross profit margin guidance for the full-year 2026 was increased to between 67.0% and 67.5%.
- 5
The company expanded its global injectable portfolio with the addition of Profhilo® in the U.S. and the expansion of the Estyme® franchise into Canada, Australia, and New Zealand.
- 6
Total purchasing accounts increased by approximately 600 in the second quarter, with over 18,600 customers having purchased from Evolus since launch.
Management Comments
David Moatazedi
The increasing momentum of our portfolio focus has resulted in Evolus gaining significant share across injectable aesthetics during the second quarter, supported by double-digit growth for Jeuveau® and accelerating adoption of Evolysse®. We delivered another quarter of consistent execution, highlighted by 21% revenue growth and a third consecutive quarter of positive Adjusted EBITDA, representing a $12.6 million improvement over the prior-year period. Based on our first-half results, we are raising our full-year 2026 financial outlook while continuing to invest in strategic opportunities that strengthen our long-term growth profile. At the same time, the injectable aesthetics market strengthened during the quarter, with improving consumer demand and stable treatment intervals driving mid-single digit growth in the neurotoxin market and, importantly, the hyaluronic acid category returning to positive growth following two years of declines. Beyond our strong commercial performance, we continued advancing our strategy to build a diversified global injectable aesthetics company. Recently, we strengthened our long-term innovation pipeline through our exclusive U.S. partnership with IBSA to develop and commercialize Profhilo®, the market-leading skin quality injectable in Europe, expanding our portfolio into a third injectable category. In the second quarter, we successfully launched the Estyme® collection of injectable hyaluronic acid gels across Europe, establishing our international HA platform. Building on that momentum, we also expanded our exclusive licensing agreement with Symatese to include Canada, Australia, and New Zealand, positioning Evolus to commercialize a complementary HA gel portfolio across every market where we currently offer Jeuveau® and Nuceiva®. Finally, we continued advancing Evolysse® Sculpt through the FDA review process and remain confident in the product’s long-term opportunity. Together, these milestones demonstrate the strength of our commercial platform and reinforce our ability to attract category leading partners across the global aesthetics market.
Informational and educational content only. Not investment advice.